 |
市場調查報告書
商品編碼
2160346
個人化免疫療法市場規模、佔有率和成長分析：按免疫療法類型、生物標記、疾病、治療環境、終端用戶產業和地區分類－2026-2033年產業預測Personalized Immunotherapy Market Size, Share, and Growth Analysis, By Immunotherapy Type, By Biomarker, By Disease Type, By Treatment Setting, By End-Use Industry, By Region - Industry Forecast 2026-2033 |
||||||
2024 年全球個人化免疫療法市場價值 840 億美元，預計到 2033 年將從 2025 年的 934.1 億美元成長到 2183.9 億美元，預測期（2026-2033 年）的複合年成長率為 11.2%。
隨著針對個人基因和免疫特徵量身定做的療法重新定義腫瘤學，全球個人化免疫療法市場正經歷變革性成長。個人化療法能夠有效將以往無法治癒的腫瘤轉化為可控制疾病，同時最大限度地降低毒性，因此獲得了廣泛認可。先進的生物標記發現技術和多組體學正在不斷發展，從而實現精準的患者分層並提高臨床成功率。人工智慧驅動的生物標記識別正在變革整個產業，透過預測患者對特定療法的反應，加速標靶識別並最佳化臨床試驗設計。這些進步刺激了製藥公司的投資，並透過縮短產品上市時間，塑造了一個充滿活力、以患者為中心的市場。隨著醫療保健系統擴大將預算分配給基於價值的醫療模式，保險公司更廣泛的接受度正在促進持續創新，尤其是在包括固體癌在內的多種癌症適應症領域。
全球個人化免疫療法市場的促進因素
全球個人化免疫療法市場的主要驅動力是基因定序技術的顯著進步。這項技術能夠精準辨識腫瘤特異性抗原，進而實現針對個別患者的客製化治療。這種高精準度不僅降低了脫靶效應，也提高了臨床療效，增強了臨床醫師和病患的信心。隨著醫療專業人員見證患者療效的改善，採用個人化免疫療法的趨勢日益成長，這反過來又刺激了研發投入，並拓展了創新療法的研發開發平臺。此外，具有科學價值的療法獲得監管部門的批准，簡化了核准流程，促進了商業性應用和產能擴張。
全球個人化免疫療法市場的限制因素
全球個人化免疫療法市場面臨許多限制因素，其中之一便是針對個別患者量身定做的生產流程高成本。這些流程需要無菌環境、專用設備和訓練有素的人員，導致生產成本增加和前置作業時間延長。此類經濟負擔可能會阻礙醫療機構採用個人化免疫療法，尤其是在資源匱乏的環境中。此外，高成本也會影響保險公司的決策，可能導致保險覆蓋範圍受限和使用指南的嚴格限制。因此，這種複雜的成本結構成為實現廣泛市場滲透的主要障礙，並可能阻礙對相關研究活動的投入。
全球個人化免疫療法市場趨勢
全球個人化免疫療法市場正經歷重大變革，其特點是現成的異體細胞療法與傳統自體細胞療法迅速融合。這項模式轉移的主要驅動力是患者對更快治療和更廣泛治療途徑的需求。基因編輯技術的創新降低了移植物抗宿主疾病（GVHD）的風險，使生產商能夠有效地擴大標準化細胞株的生產規模。因此，醫療機構正在採用結合細胞療法和查核點抑制劑的多樣化免疫療法策略，這加速了臨床應用，重新定義了腫瘤和罕見疾病的治療，並擴大了保險公司的報銷範圍。
目錄
介紹
- 調查目的
- 市場定義和範圍
調查方法
- 研究過程
- 二級資料和一級資料的方法
- 市場規模估算方法
執行摘要
- 全球市場展望
- 市場主要亮點
- 細分市場概覽
- 競爭環境概述
市場動態及展望
- 總體經濟指標
- 促進者和機會
- 抑制因素和挑戰
- 供給面趨勢
- 需求面趨勢
- 波特的分析和影響
- 競爭公司之間的競爭
- 替代品的威脅
- 買方的議價能力
- 新進入者的威脅
- 供應商的議價能力
關鍵市場分析
- 關鍵成功因素
- 影響市場的因素
- 主要投資機會
- 生態系測繪
- 2025年市場魅力指數
- PESTLE分析
- 監理情勢
全球個人化免疫療法市場規模：依免疫療法類型分類
- 個人化癌症疫苗
- 過繼性細胞療法
- 個人化查核點抑制劑療法
- 個人化單株抗體療法
- 其他
全球個人化免疫療法市場規模：依生物標記分類
- 腫瘤特異性新抗原
- PD-L1
- 腫瘤突變負荷
- 微衛星不穩定性
- 其他
全球個人化免疫療法市場規模：依疾病類型分類
- 固體癌
- 骨髓惡性腫瘤
- 自體免疫疾病
- 其他
全球個人化免疫療法市場規模：依治療環境分類
- 臨床試驗
- 住院治療
- 專科癌症中心
- 其他
全球個人化免疫療法市場規模：依最終用途產業分類
- 製藥和生物技術
- 醫院和癌症中心
- 研究機構
- 診斷檢查室
- 其他
全球個人化免疫療法市場規模：按地區分類
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
- 拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
- 中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家
競爭資訊
- 前五大公司對比
- 主要公司2025年的市場定位
- 主要市場公司採取的策略
- 近期市場趨勢
- 企業市場占有率分析，2025 年
- 主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）
主要公司簡介
- Roche
- Novartis
- Bristol Myers Squibb
- Merck & Co.
- Johnson & Johnson
- Pfizer
- AstraZeneca
- Gilead Sciences
- Amgen
- Regeneron Pharmaceuticals
- BioNTech
- Moderna
- Adaptimmune
- Cellectis
- Allogene Therapeutics
- Kite Pharma
- Immatics
- Autolus Therapeutics
- Iovance Biotherapeutics
- Neogene Therapeutics
結論與建議
Global Personalized Immunotherapy Market size was valued at USD 84.0 Billion in 2024 and is poised to grow from USD 93.41 Billion in 2025 to USD 218.39 Billion by 2033, growing at a CAGR of 11.2% during the forecast period (2026-2033).
The global personalized immunotherapy market is experiencing transformative growth as treatments tailored to individual genetic and immunologic profiles redefine oncology. By effectively converting previously untreatable tumors into manageable diseases while minimizing toxicity, personalized approaches have gained traction. The use of advanced biomarker discovery and multi-omics has evolved, enabling precise patient stratification and enhancing clinical success rates. AI-driven biomarker identification is reshaping the landscape, facilitating rapid target identification and optimizing trial designs by predicting patient responses to specific treatments. This evolution stimulates pharmaceutical investment and accelerates time-to-market, leading to a dynamic and patient-centric market. As healthcare systems increasingly allocate budgets for value-based care, this encourages broader payer acceptance and fosters ongoing innovation across various cancer indications, notably solid tumors.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Personalized Immunotherapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Personalized Immunotherapy Market Segments Analysis
Global personalized immunotherapy market is segmented by immunotherapy type, biomarker, disease type, treatment setting, end-use industry and region. Based on immunotherapy type, the market is segmented into Personalized Cancer Vaccines, Adoptive Cell Therapy, Personalized Checkpoint Inhibitor Therapy, Personalized Monoclonal Antibody Therapy and Others. Based on biomarker, the market is segmented into Tumor-Specific Neoantigens, PD-L1, Tumor Mutational Burden, Microsatellite Instability and Others. Based on disease type, the market is segmented into Solid Tumors, Hematological Malignancies, Autoimmune Diseases and Others. Based on treatment setting, the market is segmented into Clinical Trials, Hospital-Based Treatment, Specialty Cancer Centers and Others. Based on end-use industry, the market is segmented into Pharmaceutical & Biotechnology, Hospitals & Cancer Centers, Research Institutions, Diagnostic Laboratories and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Personalized Immunotherapy Market
The Global Personalized Immunotherapy market is primarily driven by significant advancements in genetic sequencing that facilitate the accurate identification of tumor-specific antigens, leading to customized therapies for individual patients. This precision not only decreases off-target effects but also enhances clinical responses, instilling greater confidence among both clinicians and patients. As healthcare professionals witness improved patient outcomes, there is a greater inclination to embrace personalized immunotherapy protocols, which, in turn, catalyzes investment in research and broadens the development pipeline for innovative treatments. Additionally, the acknowledgment of scientific value by regulatory agencies fosters smoother approval processes, promoting commercial adoption and the scaling of production capacities.
Restraints in the Global Personalized Immunotherapy Market
The Global Personalized Immunotherapy market faces significant constraints due to the high costs associated with manufacturing processes tailored to individual patients. These processes require sterile environments, specialized equipment, and highly trained staff, which contribute to increased production expenses and longer lead times. Such financial burdens may deter healthcare providers from embracing personalized immunotherapies, particularly in settings with limited resources. Additionally, the high costs can affect insurance provider decisions, leading to restricted coverage options or stringent guidelines for usage. As a result, this complex cost structure serves as a major obstacle to achieving extensive market penetration and can hinder investment in corresponding research efforts.
Market Trends of the Global Personalized Immunotherapy Market
The Global Personalized Immunotherapy market is experiencing a significant transformation, marked by the burgeoning integration of off-the-shelf allogeneic cell therapies alongside traditional autologous approaches. This paradigm shift is largely driven by the demand for expedited treatment options and enhanced accessibility for a broader patient demographic. Innovations in gene editing technologies are mitigating the risks associated with graft-versus-host diseases, allowing manufacturers to scale the production of standardized cell lines effectively. Consequently, healthcare providers are adopting multimodal immunotherapy strategies that blend cellular therapies with checkpoint inhibitors, thereby accelerating clinical adoption, redefining treatment methodologies in oncology and rare diseases, and improving payer reimbursement opportunities.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porter's Analysis & Impact
- Competitive Rivalry
- Threat of Substitutes
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Personalized Immunotherapy Market Size by Immunotherapy Type & CAGR (2026-2033)
- Market Overview
- Personalized Cancer Vaccines
- Adoptive Cell Therapy
- Personalized Checkpoint Inhibitor Therapy
- Personalized Monoclonal Antibody Therapy
- Others
Global Personalized Immunotherapy Market Size by Biomarker & CAGR (2026-2033)
- Market Overview
- Tumor-Specific Neoantigens
- PD-L1
- Tumor Mutational Burden
- Microsatellite Instability
- Others
Global Personalized Immunotherapy Market Size by Disease Type & CAGR (2026-2033)
- Market Overview
- Solid Tumors
- Hematological Malignancies
- Autoimmune Diseases
- Others
Global Personalized Immunotherapy Market Size by Treatment Setting & CAGR (2026-2033)
- Market Overview
- Clinical Trials
- Hospital-Based Treatment
- Specialty Cancer Centers
- Others
Global Personalized Immunotherapy Market Size by End-Use Industry & CAGR (2026-2033)
- Market Overview
- Pharmaceutical & Biotechnology
- Hospitals & Cancer Centers
- Research Institutions
- Diagnostic Laboratories
- Others
Global Personalized Immunotherapy Market Size & CAGR (2026-2033)
- North America (Immunotherapy Type, Biomarker, Disease Type, Treatment Setting, End-Use Industry)
- US
- Canada
- Europe (Immunotherapy Type, Biomarker, Disease Type, Treatment Setting, End-Use Industry)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Immunotherapy Type, Biomarker, Disease Type, Treatment Setting, End-Use Industry)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Immunotherapy Type, Biomarker, Disease Type, Treatment Setting, End-Use Industry)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Immunotherapy Type, Biomarker, Disease Type, Treatment Setting, End-Use Industry)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BioNTech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Moderna
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Adaptimmune
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cellectis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Allogene Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kite Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Immatics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Autolus Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Iovance Biotherapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Neogene Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
基因免疫療法市場規模、佔有率和成長分析：按治療領域、表達平台、最終用戶和地區分類－2026-2033年產業預測
全球 CD70標靶治療：臨床創新、市場趨勢、治療方法、技術平台和臨床試驗洞察（2026 年）
伊沙貝隆市場規模、佔有率和成長分析：按適應症、療法、治療階段、分銷管道、最終用戶和地區分類－2026-2033年產業預測全球 DLL3 標靶治療市場：市場機會、已通過核准療法銷售、定價、專有開發平台和臨床試驗洞察（2030 年）全球 Claudin 18.2 標靶治療市場機會、治療方法、已核准藥物定價、銷售及臨床試驗展望（2030 年）CD40標靶治療藥的全球市場:臨床試驗，治療方法，專利技術平台，市場機會相關洞察(2026年)OX40標靶治療藥的臨床試驗，治療方法，專利技術平台，市場機會(2026年)CD5標靶治療藥的全球市場:市場趨勢，臨床試驗，技術平台，未來預測(2025年)